All In Biotech

Investigational drug · Phase 2

JT002

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Seasonal Allergic Rhinitis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

2

Any phase or sponsor naming "JT002"

First trial start

2025

Feb 24, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "JT002", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Seasonal Allergic Rhinitis

Approved drugs for the same conditions: Allergies (allergic rhinitis)

Largest trials

Live from ClinicalTrials.gov: studies naming "JT002" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Seasonal Allergic Rhinitis

  • LP-003SinglePhase 39 trials

    Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies

  • SHR-1819Phase 38 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Seasonal Allergic Rhinitis, Moderate to Severe Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis

  • Shanghai Mabgeek Biotech.Co.Ltd · Atopic Dermatitis, Seasonal Allergic Rhinitis, Chronic Spontaneous Urticaria (CSU)

  • TQH2722Phase 33 trials

    Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Seasonal Allergic Rhinitis, Atopic Dermatitis

  • AK139Phase 26 trials

    Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria

  • TQC2938Phase 22 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Chronic Obstructive Pulmonary Disease, Seasonal Allergic Rhinitis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.